A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Effect Of CP-778,875 On HDL-Cholesterol In Adult Subjects With Dyslipidemia And Type 2 Diabetes Mellitus.
Phase of Trial: Phase II
Latest Information Update: 12 May 2009
At a glance
- Drugs CP 778875 (Primary)
- Indications Dyslipidaemias; Lipid metabolism disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 15 Aug 2008 Primary endpoint results published in American Journal of Cardiology
- 10 Aug 2007 Status changed from recruiting to completed.
- 25 Jun 2007 New trial record.